Day 3 Highlights - ESC Congress 2019

00:07:59

3 years 13 Views

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://cardiologytalk.com/channel/_5feba5631406a/videoEmbed/90/day-3-highlights-%7C-esc-congress-2019?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://cardiologytalk.com/channel/_5feba5631406a/videoEmbed/90/day-3-highlights-%7C-esc-congress-2019?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://cardiologytalk.com/channel/_5feba5631406a/videoEmbed/90/day-3-highlights-%7C-esc-congress-2019?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://cardiologytalk.com/channel/_5feba5631406a/video/90"><img src="https://cardiologytalk.com/view/img/video-placeholder-gray-portrait.webp?cache=1693571558_1693571558">Day 3 Highlights | ESC Congress 2019</a>

Link (BBCode):

[url=https://cardiologytalk.com/channel/_5feba5631406a/video/90][img]https://cardiologytalk.com/view/img/video-placeholder-gray-portrait.webp?cache=1693571558_1693571558[/img]Day 3 Highlights | ESC Congress 2019[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Acute Coronary Syndromes

Description:

Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease (AFIRE—0:35); effects of sacubitril-valsartan compared with enalapril on arterial hemodynamics and cardiac remodeling in patients with heart failure and reduced ejection fraction (EVALUATE-HF, PROVE-HF—4:39); using cardiolinguistics and artificial intelligence to reframe typical and atypical angina (HERMES—4:45), and the combined effect of lower LDL-C and lower systolic blood pressure on the lifetime risk of cardiovascular disease (LDL SBP—6:15). Visit https://www.acc.org/esc2019 for full meeting coverage.

Up next